Gentex Corp (GNTX) Reports In-Line Q3 EPS, Trims FY Revenue Guidance
Tweet
Share
E-mailGet Alerts GNTX Hot Sheet
Price: $22.24 -0.98%
Revenue Growth %: +2.7%
Financial Fact:
Other, net: -800.86K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +2.7%
Financial Fact:
Other, net: -800.86K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Gentex Corp (NASDAQ: GNTX) reported Q3 EPS of $0.42, in-line with the analyst estimate of $0.42. Revenue for the quarter came in at $460.3 million versus the consensus estimate of $467.94 million.
GUIDANCE:
Gentex Corp sees FY2018 revenue of $1.854-1.872 billion, versus the consensus of $1.88 billion.
| 2018 Calendar Year Guidance | ||
| Annual Guidance | ||
| Item | As of 7/20/18 | Updated as of 10/19/18 |
| Net Sales | $1.88 - $1.91 billion | $1.854 - $1.872 billion |
| Gross Margin (includes additional tariff costs) | 37.5% - 38.5% | 37.5% - 38.0% |
| Operating Expenses (E,R&D and S,G&A) | $180 - $185 million | no change |
| Tax Rate (excluding discrete items) | 15 - 18% | no change |
| Capital Expenditures | $110 - $120 million | $95 - $105 million |
| Depreciation & Amortization | $105 - $115 million | $105 - $110 million |
For earnings history and earnings-related data on Gentex Corp (GNTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
